Allogene Therapeutics Inc (ALLO)
1.5700 x 1 1.6200 x 1
Pre-market by (Cboe BZX)
1.5700 -0.0300 (-1.88%) 03/26/25 [NASDAQ]
1.5700 x 1 1.6200 x 1
Pre-market 1.5700 unch (unch) 06:45 ET
for Wed, Mar 26th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 75,218 | 83,155 | 61,904 | 173,314 | 183,351 |
Marketable Securities | 217,258 | 365,542 | 455,416 | 283,988 | 644,559 |
TOTAL | $303,386 | $459,115 | $528,824 | $471,323 | $845,130 |
Non-Current Assets | |||||
PPE Net | 86,056 | 99,478 | 112,839 | 122,990 | 118,840 |
Investments And Advances | 80,673 | 3,645 | 76,468 | 382,378 | 207,946 |
Other Non-Current Assets | 78,595 | 80,599 | 103,448 | 74,137 | 55,913 |
TOTAL | $245,324 | $183,722 | $292,755 | $579,505 | $382,699 |
Total Assets | $548,710 | $642,837 | $821,579 | $1,050,828 | $1,227,829 |
Liabilities | |||||
Current Liabilities | |||||
Accounts payable and accrued liabilities | 5,394 | 5,897 | 13,890 | 10,255 | 10,390 |
Accrued Expenses | 30,129 | 31,182 | 39,743 | 37,496 | 44,938 |
TOTAL | $35,523 | $37,079 | $53,728 | $47,907 | $94,320 |
Non-Current Liabilities | |||||
Deferred Revenues | N/A | N/A | 95 | 156 | 38,992 |
aiOther Non-Current Liabilities | 91,008 | 93,525 | 100,969 | 77,721 | 53,892 |
TOTAL | $91,008 | $93,525 | $100,969 | $77,721 | $53,892 |
Total Liabilities | $126,531 | $130,604 | $154,697 | $125,628 | $148,212 |
Shareholders' Equity | |||||
Shares Outstanding, K | 217,265 | 169,092 | 144,497 | 142,752 | 140,648 |
Common Shares | 212 | 169 | 144 | 142 | 140 |
Retained earnings | -1,819,823 | -1,562,233 | -1,234,968 | -894,554 | -646,343 |
Other shareholders' equity | -89 | -955 | -9,926 | -2,567 | 268 |
TOTAL | $422,179 | $512,233 | $666,882 | $925,200 | $1,079,617 |
Total Liabilities And Equity | $548,710 | $642,837 | $821,579 | $1,050,828 | $1,227,829 |